Abbott Labs Makes Marketing Push For New Glucose Monitors, Targets Health-Conscious Consumers
Portfolio Pulse from Vandana Singh
Abbott Laboratories (NYSE: ABT) is launching a marketing campaign for its new glucose monitoring device, Lingo, targeting health-conscious consumers. The device aims to provide personalized health data and insights. Abbott also plans to launch Libre Rio, an over-the-counter CGM system for people with Type 2 diabetes. Abbott competes with DexCom Inc (NASDAQ: DXCM) and Medtronic Plc (NYSE: MDT) in the continuous glucose monitoring market.
July 19, 2024 | 3:10 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Abbott Laboratories is launching a marketing campaign for its new glucose monitoring device, Lingo, targeting health-conscious consumers. The company also plans to launch Libre Rio, an over-the-counter CGM system for people with Type 2 diabetes.
The launch of Lingo and Libre Rio, along with a strong marketing push, is likely to drive sales growth for Abbott Laboratories. The company's focus on health-conscious consumers and people with Type 2 diabetes presents significant market opportunities.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100
NEGATIVE IMPACT
DexCom Inc competes with Abbott Laboratories in the continuous glucose monitoring market. Abbott's launch of Lingo and Libre Rio could impact DexCom's market share.
Abbott's new product launches and marketing efforts could pose a competitive threat to DexCom, potentially impacting its market share in the continuous glucose monitoring market.
CONFIDENCE 80
IMPORTANCE 70
RELEVANCE 50
NEGATIVE IMPACT
Medtronic Plc competes with Abbott Laboratories in the continuous glucose monitoring market. Abbott's launch of Lingo and Libre Rio could impact Medtronic's market share.
Abbott's new product launches and marketing efforts could pose a competitive threat to Medtronic, potentially impacting its market share in the continuous glucose monitoring market.
CONFIDENCE 80
IMPORTANCE 70
RELEVANCE 50